Broad-Spectrum Antiviral Protein: Stable and Soluble Griffithsin Mutants (20072, 20048, 19051, 15042, etc.)

  • Potent antiviral protein with activity against HIV, SARS-CoV, and other viruses.
  • Possesses microbicidal and antifungal capabilities.
  • Proven safe in single dose Phase 1a clinical trials. Phase 1b multiple dose clinical trials ongoing.

Abstract

With the COVID-19 pandemic and a continually emerging range of harmful and contagious viruses, there is an urgent need for effective, scalable antiviral agents. To meet this need, researchers at the University of Louisville have developed a broad-spectrum antiviral drug substance called Q‑Griffithsin, which is a variant of the red algal lectin protein called Griffithsin.

Contact Information

Name: Rob Smith

Email: robert.smith.6@louisville.edu

Phone: 502-852-3027